FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911192406> ?p ?o ?g. }

• W2911192406 abstract "Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the presence of t(9;22) chromosomal translocation that results in BCR-ABL fusion gene. ABL tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, and dasatinib, are currently the front-line treatment options for CML. Recently, natural killer (NK) cell activation and expansion have been shown to be associated with the optimal molecular responses of TKI treatments for CML. To investigate the effects and mechanisms of these TKIs on NK cells, sorted CD3-CD16+CD56dim and CD3-CD16+CD56bright NK cells from CML patients in chronic phase (CP) were characterized by their expressions of NK activating and inhibitory receptors. The expressions of activating receptors including NKG2D, natural cytotoxicity receptor (NCR) and DNAM-1, increase equally during the TKI treatments for CML. In this report, we uncovered that the levels of inhibitory receptors, such as NKG2A and killer cell immunoglobulin-like receptor (KIR) 3DL1, were significantly lower on NK cells in the CML patients treated with dasatinib than in the patients treated with imatinib or nilotinib. Interestingly, CML patients treated with dasatinib expressed fewer NKG2A+ NK cells, which provide negative signals for NK-mediated cytotoxicity. For these dasatinib-treated patients, the duration to achieve the major molecular response (MMR) also was significantly correlated with NKG2A+ NK cell expression. These unique effects on NKG2A expression were not observed in patients on imatinib or nilotinib. In line with NKG2A down-regulation by dasatinib, NK-cell cytotoxicity evaluated by the killing assay was significantly higher in patients treated with dasatinib than in those treated with imatinib or nilotinib. The lower NK cytotoxicity in patients treated with imatinib or nilotinib could be restored by NKG2A blockade using anti-NKG2A antibody. Further in vitro experiments revealed mechanistically that dasatinib could inactivate p38 mitogen-activated protein kinase (MAPK), and consequently affect nuclear localization of GATA-3 and expression of NKG2A. Our results highlight the dual effects of dasatinib in direct inhibition of ABL kinase and in immunomodulation through down-regulating the NKG2A+ NK population, contributing to the shorter optimal molecular responses (MR) during CML treatments." @default.
• W2911192406 created "2019-01-25" @default.
• W2911192406 creator A5002959119 @default.
• W2911192406 creator A5023461073 @default.
• W2911192406 creator A5027826296 @default.
• W2911192406 creator A5044314163 @default.
• W2911192406 creator A5066377208 @default.
• W2911192406 creator A5081572683 @default.
• W2911192406 creator A5082072958 @default.
• W2911192406 creator A5086063519 @default.
• W2911192406 date "2019-01-17" @default.
• W2911192406 modified "2023-09-25" @default.
• W2911192406 title "NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia" @default.
• W2911192406 cites W1511105405 @default.
• W2911192406 cites W15742580 @default.
• W2911192406 cites W1640048168 @default.
• W2911192406 cites W1968685079 @default.
• W2911192406 cites W1968747503 @default.
• W2911192406 cites W1972178991 @default.
• W2911192406 cites W1976194065 @default.
• W2911192406 cites W1986139301 @default.
• W2911192406 cites W1990406235 @default.
• W2911192406 cites W1994111355 @default.
• W2911192406 cites W1997849135 @default.
• W2911192406 cites W1998593414 @default.
• W2911192406 cites W2010109350 @default.
• W2911192406 cites W2013435992 @default.
• W2911192406 cites W2014208459 @default.
• W2911192406 cites W2021073739 @default.
• W2911192406 cites W2023082289 @default.
• W2911192406 cites W2027863196 @default.
• W2911192406 cites W2034892057 @default.
• W2911192406 cites W2051693138 @default.
• W2911192406 cites W2053441255 @default.
• W2911192406 cites W2068967489 @default.
• W2911192406 cites W2073035156 @default.
• W2911192406 cites W2074301005 @default.
• W2911192406 cites W2082751900 @default.
• W2911192406 cites W2097760084 @default.
• W2911192406 cites W2097799776 @default.
• W2911192406 cites W2098930452 @default.
• W2911192406 cites W2100053995 @default.
• W2911192406 cites W2102631852 @default.
• W2911192406 cites W2105780433 @default.
• W2911192406 cites W2116171543 @default.
• W2911192406 cites W2124196948 @default.
• W2911192406 cites W2141436376 @default.
• W2911192406 cites W2143939343 @default.
• W2911192406 cites W2144891041 @default.
• W2911192406 cites W2146313292 @default.
• W2911192406 cites W2148582892 @default.
• W2911192406 cites W2158196950 @default.
• W2911192406 cites W2162947108 @default.
• W2911192406 cites W2163961206 @default.
• W2911192406 cites W2189113171 @default.
• W2911192406 cites W2201929875 @default.
• W2911192406 cites W2231399813 @default.
• W2911192406 cites W2490657737 @default.
• W2911192406 cites W2515527586 @default.
• W2911192406 cites W2552724266 @default.
• W2911192406 cites W2557854027 @default.
• W2911192406 cites W2564723173 @default.
• W2911192406 cites W2567928490 @default.
• W2911192406 cites W2589987575 @default.
• W2911192406 cites W2592060299 @default.
• W2911192406 cites W2680135673 @default.
• W2911192406 doi "https://doi.org/10.3389/fimmu.2018.03152" @default.
• W2911192406 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6344416" @default.
• W2911192406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30705677" @default.
• W2911192406 hasPublicationYear "2019" @default.
• W2911192406 type Work @default.
• W2911192406 sameAs 2911192406 @default.
• W2911192406 citedByCount "29" @default.
• W2911192406 countsByYear W29111924062019 @default.
• W2911192406 countsByYear W29111924062020 @default.
• W2911192406 countsByYear W29111924062021 @default.
• W2911192406 countsByYear W29111924062022 @default.
• W2911192406 countsByYear W29111924062023 @default.
• W2911192406 crossrefType "journal-article" @default.
• W2911192406 hasAuthorship W2911192406A5002959119 @default.
• W2911192406 hasAuthorship W2911192406A5023461073 @default.
• W2911192406 hasAuthorship W2911192406A5027826296 @default.
• W2911192406 hasAuthorship W2911192406A5044314163 @default.
• W2911192406 hasAuthorship W2911192406A5066377208 @default.
• W2911192406 hasAuthorship W2911192406A5081572683 @default.
• W2911192406 hasAuthorship W2911192406A5082072958 @default.
• W2911192406 hasAuthorship W2911192406A5086063519 @default.
• W2911192406 hasBestOaLocation W29111924061 @default.
• W2911192406 hasConcept C109316439 @default.
• W2911192406 hasConcept C114684123 @default.
• W2911192406 hasConcept C126322002 @default.
• W2911192406 hasConcept C167672396 @default.
• W2911192406 hasConcept C170493617 @default.
• W2911192406 hasConcept C183193105 @default.
• W2911192406 hasConcept C185592680 @default.
• W2911192406 hasConcept C202751555 @default.
• W2911192406 hasConcept C203014093 @default.
• W2911192406 hasConcept C2776062744 @default.
• W2911192406 hasConcept C2777413986 @default.
• W2911192406 hasConcept C2777583451 @default.

• next